This year’s Conference offers a wide variety of sessions for attendees, and will feature distinguished speakers from all around the world, relevant stakeholders and experts, to delve into the latest innovations in paediatrics.

From 24 to 26 June 2026, Cancer Patients Europe will host its Annual Meeting in Brussels, bringing together patient advocates, policymakers, healthcare stakeholders, and partners from across the cancer community.

Europe stands at a crossroads. In a world shaped by geopolitical tensions, economic fragmentation and accelerating global competition, the choices made today will determine Europe’s ability to compete, innovate and lead in the decades ahead.

The must-attend European defense strategy forum for the life sciences litigation community. Europe’s Premier Forum for Life Sciences Product Liability, Policy & Dispute Resolution.

The next ECRD will be held on 3 & 4 June 2026 in Prague and will be titled “Rare Diseases in a Changing & Competitive Europe: Shaping policies to address the unmet needs of people living with rare diseases”.  

This high-level briefing from the Financial Times, in partnership with Syneos Health, will bring together leading executives and investors to focus on what it takes to succeed in Europe’s launch environment.

The European pharmaceutical market is facing a moment of profound change. With sweeping updates to the EU pharmaceutical package, a growing maze of regulatory frameworks, and mounting global competition, the industry is grappling with a critical question: Are we at a turning point for Europe’s pharmaceutical...

Join the EFGCP Conference 2026 in Brussels to explore how ethical review systems can strengthen Europe’s clinical research landscape.

Europe stands at a critical moment for its life sciences sector. Across the world, governments are actively strengthening their biotechnology ecosystems through investment, faster regulatory systems and targeted industrial strategies.

Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity in Europe, despite significant advances in treatment. Late diagnosis, inconsistent screening approaches, variability in care pathways, and gaps in preventive action continue to hinder progress.

At a time when health budgets are strained, public finances are under pressure, the health workforce crisis is deepening, and Europe faces unprecedented geopolitical challenges, we need to rethink healthcare.